Reply button not working for me..
@stockrock
No worries mate, nothing next to the amount of research you put in. Good points. A couple of warning shots fired there by Jen.. What I like is CLTX is super unique in its molecular makeup and the exclusive IP is CHM’s. Unlike other Immuno-oncology companies on the ASX going after similar malignancies (without naming any specifically) The data readout could confirm CLTX will not need any partnerships or enhancements to treat GBM efficaciously IMO. CHM-1101 could be slotted away early for a handsome sum by any of the big guys at anytime. I personally hope CHM takes it all the way themselves. I agree little hint there that a hematological target could be the next acquisition then maybe an NK Cell or Marcophage.
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
0.4¢ |
Change
0.000(0.00%) |
Mkt cap ! $8.060M | |||
| Open | High | Low | Value | Volume |
| 0.4¢ | 0.4¢ | 0.4¢ | $50.77K | 12.69M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 2602327 | 0.4¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.5¢ | 18629873 | 23 |
View Market Depth
| Last trade - 15.15pm 25/06/2025 (20 minute delay) ? |
| CHM (ASX) Chart |